Navigation Links
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

t candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
2. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
5. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
6. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
7. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
10. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
11. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... Oct. 20, 2014   Taiho Oncology, Inc. ... ( Japan ), announced that the ... Track designation for TAS-102 (nonproprietary names: trifluridine and ... investigation for the treatment of refractory metastatic colorectal ... a rolling NDA submission to the FDA. According ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... 20, 2014 ASCNYC (ascnyc.org) is ... helps New Yorkers living with HIV/AIDS and other ... housing, recovery and self-sufficiency. Each year, ASCNYC spotlights ... community through their tireless efforts. , Savills ... , has been selected as this year’s honoree ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... , SAN FRANCISCO, CA February 2, 2010 -- ... coronary heart disease worldwide, only some obese individuals go ... relatively protected. Defining these protective factors could help scientists ... this end, a research team at the Gladstone Institute ...
... , , KNOXVILLE, Tenn. , ... TMH ), one of the largest suppliers of outsourced healthcare ... in the United States , today announced that the Company ... the market closes on Tuesday, February 9, 2010 , to ...
... , SAN DIEGO , Feb. 3 For ... the top 100 integrated health care networks in the nation in an ... was ranked No. 6 in the nation and No. 1 in ... Modern Healthcare , is regarded as the nation,s premier rating system for ...
... , , TUCSON, Ariz. , ... ) today announced that Fletcher McCusker , Chairman and Chief Executive ... the UBS 20th Annual Global Healthcare Services Conference on Wednesday, February ... .   , Providence ,s presentation is scheduled for 10:00 ...
... , ... FDA is alerting the public about the following products: , ... Alli, 60 mg capsules (120-count refill kit) sold over the Internet ... Insulin Syringes may have needles that detach from the syringe and ...
... , MT. LAUREL, N.J. , Feb. ... transcription software and services, today announced that it has agreed ... provider of clinical documentation technology and services that recently filed ... place pursuant to Section 363 of the United States Bankruptcy ...
Cached Medicine News:Health News:Gladstone scientists identify target that may reduce complications of obesity 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 3Health News:Sharp HealthCare Rated Top Health Care Network in California and No. 6 in the Nation 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 3Health News:FDA Consumer Health Information - FDA's MedWatch Safety Alerts: January 2010 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 3
Inquire...
... Calf Implants are available ... sizes. They are available non-sterile ... and sold individually. Depending on ... may use one or two ...
... the IQmark family elevates your ECG and Spirometry ... cost-savings and efficient patient care. The IQmark Diagnostic ... office, clinics and medical centers as well as ... in conjunction with the IQmark Digital ECG PDA ...
... data-gathering extension of the IQmark Diagnostic Workstation, ... Windows-based PC to deliver unmatched speed, accuracy ... Now you can download and seamlessly integrate ... simple click of a mouse. The point-and-click ...
Medicine Products: